Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
Recruiting
N/A
Interventional Study
Thalassemia Intermedia
Thalassemia Major
Growth Delay
Puberty, Delayed
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- Up to 18
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 369 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
There are nearly 300,000 patients with severe or intermediate thalassemia in China. Growth retardation is the most significant health issue for children and adolescents with transfusion-dependent thalassemia (TDT), placing a substantial economic burden on their families and a serious social strain on the labor force. Investigating the growth and development of these children and adolescents, and e…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subjects diagnosed with transfusion-dependent thalassemia (TDT)
* Male or female age ≤18 years
* Subjects who are willing and able to provide written informed consent
Exclusion Criteria:
* Not applicable
Contacts